Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Lower Female Reproductive System Cancers Report Coverage 8
2.2 Cervical Cancer – Overview 8
2.3 Vaginal Cancer – Overview 8
2.4 Vulvar Cancer – Overview 8
3 Therapeutics Development 9
3.1 Cervical Cancer 9
3.2 Vaginal Cancer 24
3.3 Vulvar Cancer 27
4 Therapeutics Assessment 30
4.1 Cervical Cancer 30
4.2 Vaginal Cancer 42
4.3 Vulvar Cancer 48
5 Companies Involved in Therapeutics Development 54
5.1 Cervical Cancer 54
5.2 Vaginal Cancer 100
5.3 Vulvar Cancer 103
6 Dormant Projects 106
6.1 Cervical Cancer 106
6.2 Vaginal Cancer 110
6.3 Vulvar Cancer 110
7 Discontinued Products 111
7.1 Cervical Cancer 111
8 Product Development Milestones 112
8.1 Cervical Cancer 112
8.2 Vulvar Cancer 125
9 Appendix 128
9.1 Methodology 128
9.2 Coverage 128
9.3 Secondary Research 128
9.4 Primary Research 128
9.5 Expert Panel Validation 128
9.6 Contact Us 129
9.7 Disclaimer 129
List of Tables
Table 1: Number of Products under Development for Cervical Cancer 9
Table 2: Number of Products under Development by Companies, Cervical Cancer 11
Table 3: Number of Products under Development by Universities/Institutes, Cervical Cancer 15
Table 4: Products under Development by Companies, Cervical Cancer 16
Table 5: Products under Development by Universities/Institutes, Cervical Cancer 22
Table 6: Number of Products under Development for Vaginal Cancer 24
Table 7: Number of Products under Development by Companies, Vaginal Cancer 25
Table 8: Products under Development by Companies, Vaginal Cancer 26
Table 9: Number of Products under Development for Vulvar Cancer 27
Table 10: Number of Products under Development by Companies, Vulvar Cancer 28
Table 11: Products under Development by Companies, Vulvar Cancer 29
Table 12: Number of Products by Stage and Target, Cervical Cancer 31
Table 13: Number of Products by Stage and Mechanism of Action, Cervical Cancer 35
Table 14: Number of Products by Stage and Route of Administration, Cervical Cancer 39
Table 15: Number of Products by Stage and Molecule Type, Cervical Cancer 41
Table 16: Number of Products by Stage and Target, Vaginal Cancer 43
Table 17: Number of Products by Stage and Mechanism of Action, Vaginal Cancer 44
Table 18: Number of Products by Stage and Route of Administration, Vaginal Cancer 46
Table 19: Number of Products by Stage and Molecule Type, Vaginal Cancer 47
Table 20: Number of Products by Stage and Target, Vulvar Cancer 49
Table 21: Number of Products by Stage and Mechanism of Action, Vulvar Cancer 50
Table 22: Number of Products by Stage and Route of Administration, Vulvar Cancer 52
Table 23: Number of Products by Stage and Molecule Type, Vulvar Cancer 53
Table 24: Cervical Cancer – Pipeline by Abion Inc 54
Table 25: Cervical Cancer – Pipeline by Abivax SA 54
Table 26: Cervical Cancer – Pipeline by Admedus Ltd 55
Table 27: Cervical Cancer – Pipeline by Advaxis Inc 55
Table 28: Cervical Cancer – Pipeline by Advenchen Laboratories LLC 56
Table 29: Cervical Cancer – Pipeline by Agenus Inc 56
Table 30: Cervical Cancer – Pipeline by Amgen Inc 57
Table 31: Cervical Cancer – Pipeline by AntiCancer Inc 57
Table 32: Cervical Cancer – Pipeline by Antigen Express Inc 58
Table 33: Cervical Cancer – Pipeline by Arbor Vita Corp 58
Table 34: Cervical Cancer – Pipeline by ArQule Inc 59
Table 35: Cervical Cancer – Pipeline by Asana BioSciences LLC 59
Table 36: Cervical Cancer – Pipeline by AstraZeneca Plc 60
Table 37: Cervical Cancer – Pipeline by AVEO Pharmaceuticals Inc 60
Table 38: Cervical Cancer – Pipeline by Bayer AG 61
Table 39: Cervical Cancer – Pipeline by BeiGene Ltd 62
Table 40: Cervical Cancer – Pipeline by Bioleaders Corp 62
Table 41: Cervical Cancer – Pipeline by Biomics Biotechnologies Co Ltd 62
Table 42: Cervical Cancer – Pipeline by Blirt SA 63
Table 43: Cervical Cancer – Pipeline by Boehringer Ingelheim GmbH 63
Table 44: Cervical Cancer – Pipeline by Bristol-Myers Squibb Co 64
Table 45: Cervical Cancer – Pipeline by Cadila Healthcare Ltd 64
Table 46: Cervical Cancer – Pipeline by Cancer Research Technology Ltd 65
Table 47: Cervical Cancer – Pipeline by Celleron Therapeutics Ltd 65
Table 48: Cervical Cancer – Pipeline by Coherus BioSciences Inc 66
Table 49: Cervical Cancer – Pipeline by Critical Outcome Technologies Inc 66
Table 50: Cervical Cancer – Pipeline by Cytori Therapeutics Inc 67
Table 51: Cervical Cancer – Pipeline by CZ BioMed Corp 67
Table 52: Cervical Cancer – Pipeline by DelMar Pharmaceuticals Inc 68
Table 53: Cervical Cancer – Pipeline by Dr. Reddy's Laboratories Ltd 68
Table 54: Cervical Cancer – Pipeline by Eisai Co Ltd 69
Table 55: Cervical Cancer – Pipeline by Etubics Corp 69
Table 56: Cervical Cancer – Pipeline by Eureka Therapeutics Inc 70
Table 57: Cervical Cancer – Pipeline by EyeGene Inc 70
Table 58: Cervical Cancer – Pipeline by F. Hoffmann-La Roche Ltd 71
Table 59: Cervical Cancer – Pipeline by Formune SL 71
Table 60: Cervical Cancer – Pipeline by GamaMabs Pharma SA 72
Table 61: Cervical Cancer – Pipeline by Gene Techno Science Co Ltd 72
Table 62: Cervical Cancer – Pipeline by Genentech Inc 73
Table 63: Cervical Cancer – Pipeline by Genmab A/S 73
Table 64: Cervical Cancer – Pipeline by Genor BioPharma Co Ltd 74
Table 65: Cervical Cancer – Pipeline by GlaxoSmithKline Plc 74
Table 66: Cervical Cancer – Pipeline by Glycostem Therapeutics BV 75
Table 67: Cervical Cancer – Pipeline by Glycotope GmbH 75
Table 68: Cervical Cancer – Pipeline by Gradalis Inc 76
Table 69: Cervical Cancer – Pipeline by Immunomedics Inc 76
Table 70: Cervical Cancer – Pipeline by Immunovaccine Inc 77
Table 71: Cervical Cancer – Pipeline by Innate Pharma SA 77
Table 72: Cervical Cancer – Pipeline by Innovation Pharmaceuticals Inc 78
Table 73: Cervical Cancer – Pipeline by Iovance Biotherapeutics Inc 78
Table 74: Cervical Cancer – Pipeline by ISA Pharmaceuticals BV 79
List of Figures
Figure 1: Number of Products under Development for Cervical Cancer 9
Figure 2: Number of Products under Development by Companies, Cervical Cancer 10
Figure 3: Number of Products under Development by Universities/Institutes, Cervical Cancer 14
Figure 4: Number of Products under Development for Vaginal Cancer 24
Figure 5: Number of Products under Development by Companies, Vaginal Cancer 25
Figure 6: Number of Products under Development for Vulvar Cancer 27
Figure 7: Number of Products under Development by Companies, Vulvar Cancer 28
Figure 8: Number of Products by Top 10 Targets, Cervical Cancer 30
Figure 9: Number of Products by Stage and Top 10 Targets, Cervical Cancer 30
Figure 10: Number of Products by Top 10 Mechanism of Actions, Cervical Cancer 34
Figure 11: Number of Products by Stage and Top 10 Mechanism of Actions, Cervical Cancer 34
Figure 12: Number of Products by Routes of Administration, Cervical Cancer 38
Figure 13: Number of Products by Stage and Routes of Administration, Cervical Cancer 39
Figure 14: Number of Products by Top 10 Molecule Types, Cervical Cancer 40
Figure 15: Number of Products by Stage and Top 10 Molecule Types, Cervical Cancer 40
Figure 16: Number of Products by Targets, Vaginal Cancer 42
Figure 17: Number of Products by Stage and Targets, Vaginal Cancer 42
Figure 18: Number of Products by Mechanism of Actions, Vaginal Cancer 43
Figure 19: Number of Products by Stage and Mechanism of Actions, Vaginal Cancer 44
Figure 20: Number of Products by Routes of Administration, Vaginal Cancer 45
Figure 21: Number of Products by Stage and Routes of Administration, Vaginal Cancer 45
Figure 22: Number of Products by Molecule Types, Vaginal Cancer 46
Figure 23: Number of Products by Stage and Molecule Types, Vaginal Cancer 47
Figure 24: Number of Products by Targets, Vulvar Cancer 48
Figure 25: Number of Products by Stage and Targets, Vulvar Cancer 48
Figure 26: Number of Products by Mechanism of Actions, Vulvar Cancer 49
Figure 27: Number of Products by Stage and Mechanism of Actions, Vulvar Cancer 50
Figure 28: Number of Products by Routes of Administration, Vulvar Cancer 51
Figure 29: Number of Products by Stage and Routes of Administration, Vulvar Cancer 51
Figure 30: Number of Products by Molecule Types, Vulvar Cancer 52
Figure 31: Number of Products by Stage and Molecule Types, Vulvar Cancer 53
Global 5-Fluorouracil Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 76
The global 5-Fluorouracil market was valued at US$ 283 million in 2023 and is anticipated to reach US$ 487.9 million by 2030, witnessing a CAGR of 4.3% during The forecast period 2024-2030.
North American market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for 5-Fluorouracil is estimated to increase from $ million in 2023 to reach $ million by ......
Global Carboplatin Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 79
The global Carboplatin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Carboplatin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % d......
Global Neutropenia Drugs Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 96
The global Neutropenia Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated to increa......
Global Small Molecule Cancer Drug Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Small Molecule Cancer Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated ......
Global Capecitabine Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 80
Capecitabine is an orally-administered chemotherapeutic agent used in The treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in The tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blo......
Global Oxaliplatin Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 104
Oxaliplatin is a platinum-based anticancer drug with colorless or nearly colorless transparent liquid. It is often used for metastatic colorectal cancer treatment or adjuvant therapy The third stage colon cancer after resecting primary tumor completely.
In this report, only The finished drug is covered, exclude API.
The global Oxaliplatin market was valued at US$ 897.5 million in 2023 and is anticipated to reach US$ 1641.5 million by 2030, witnessing a CAGR of 8.9% duri......
Global Cancer Treatment Drugs Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 158
According to our LPI (LP Information) latest study, the global Cancer Treatment Drugs market size was valued at US$ 174990 million in 2023. With growing demand in downstream market, the Cancer Treatment Drugs is forecast to a readjusted size of US$ 322540 million by 2030 with a CAGR of 9.1% during review period.
The research report highlights the growth potential of the global Cancer Treatment Drugs market. Cancer Treatment Drugs are expected to show stable growth in the future market. H......
Global Capecitabine Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 93
According to our LPI (LP Information) latest study, the global Capecitabine market size was valued at US$ 1003.9 million in 2023. With growing demand in downstream market, the Capecitabine is forecast to a readjusted size of US$ 975.1 million by 2030 with a CAGR of -0.4% during review period.
The research report highlights the growth potential of the global Capecitabine market. Capecitabine are expected to show stable growth in the future market. However, product differentiation, reducin......
Global Methotrexate Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 95
According to our LPI (LP Information) latest study, the global Methotrexate market size was valued at US$ 506 million in 2023. With growing demand in downstream market, the Methotrexate is forecast to a readjusted size of US$ 613.9 million by 2030 with a CAGR of 2.8% during review period.
The research report highlights the growth potential of the global Methotrexate market. Methotrexate are expected to show stable growth in the future market. However, product differentiation, reducing co......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
